The prescribed antiarrhythmic drug, quinidine, has emerged as a precision therapy for KCNT1-related epilepsy by blocking Slack mutant variants in vitro and conferring decreased seizure frequency and improved psychomotor development in clinical treatment (Milligan et al., 2014; Bearden et al., 2014; Mikati et al., 2015; Numis et al., 2018). This evidence concerns the gene KCNT1 and epilepsy.